Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Issued (2017 - 2025)

Spyre Therapeutics (SYRE) has disclosed Shares Issued for 9 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 101.08% year-over-year to $1.7 million, compared with a TTM value of $3.3 million through Dec 2025, down 55.98%, and an annual FY2025 reading of $3.3 million, down 55.98% over the prior year.
  • Shares Issued was $1.7 million for Q4 2025 at Spyre Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $169.2 million in Q1 2024 and bottomed at -$164.3 million in Q2 2024.
  • Average Shares Issued over 5 years is $889800.0, with a median of $249000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 939927.78% in 2024, while the deepest fall reached 39936.79% in 2024.
  • Year by year, Shares Issued stood at $249000.0 in 2021, then tumbled by 84.74% to $38000.0 in 2022, then soared by 965.79% to $405000.0 in 2023, then crashed by 39936.79% to -$161.3 million in 2024, then skyrocketed by 101.08% to $1.7 million in 2025.
  • Business Quant data shows Shares Issued for SYRE at $1.7 million in Q4 2025, $1.6 million in Q3 2025, and -$161.3 million in Q4 2024.